BioXcel Therapeutics (BTAI) Equity Ratio (2017 - 2026)

BioXcel Therapeutics' Equity Ratio history runs 10 years deep, the most recent figure standing at 3.1 for Q1 2026.

• In Q1 2026, Equity Ratio fell 32.67% year-over-year to 3.1; the TTM figure through Mar 2026 stood at 3.1 (down 32.67% YoY), while the FY2025 annual figure was 2.13, up 12.48% from the prior year.
• Equity Ratio was 3.1 for Q1 2026 at BioXcel Therapeutics, down from 2.13 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.92 in Q1 2022 to a low of 4.17 in Q2 2025.
• Historically, Equity Ratio has averaged 1.08 across 5 years, with a median of 0.88 in 2024.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio slumped 2812.81% in 2024, then grew 12.48% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.37 in 2022, then plunged by 305.57% to 0.77 in 2023, then plunged by 216.73% to 2.43 in 2024, then increased by 12.48% to 2.13 in 2025, then slumped by 45.95% to 3.1 in 2026.
• The last three Equity Ratio figures came in at 3.1 (Q1 2026), 2.13 (Q4 2025), and 1.99 (Q3 2025), per Business Quant data.